Cosmos Health Sees FY26 Revenue Surpassing $90M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Cosmos Health sees FY26 revenue surpassing $90M, one est. $87.3M
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cosmos Health Projects 207% Revenue Growth by 2029
- Revenue Growth Outlook: Cosmos Health anticipates revenue will increase from $65.3 million in 2025 to $200.6 million by 2029, representing a 207% growth at a 32% CAGR, primarily driven by strong growth in pharmaceutical distribution and nutraceutical commercialization.
- Significant Gross Profit Increase: Gross profit is projected to rise 801% from $7.9 million in 2025 to $71.2 million by 2029, with gross margins expanding from 12.1% to 35.5%, reflecting a strategic shift towards higher-margin proprietary products.
- Net Income Turnaround: The company expects to achieve profitability in 2027, with net income projected to reach $31.0 million by 2029, an improvement of $50.1 million from a loss in 2025, indicating substantial gains in revenue and cost efficiencies.
- Positive Cash Flow Transition: Operating cash flow is expected to turn positive in 2027 at $11.9 million and increase to $24.0 million by 2029, demonstrating the company's shift towards a self-funding growth model.
See More
Cosmos Holdings Reports Q1 Financial Results
- Financial Performance: Cosmos Holdings reported an adjusted net loss of $996,502 for Q1, indicating challenges in profitability, although revenue reached $17.93 million, suggesting potential for sales growth.
- Revenue Analysis: The company reported revenue of $65.27 million, which, despite fluctuations compared to Q1 performance, still demonstrates a degree of competitiveness in the market that may attract investor interest.
- Earnings Per Share: Cosmos Holdings' non-GAAP EPS was -$0.12, highlighting the urgency for the company to control costs and improve profitability, which could influence future investment decisions.
- Market Reaction: Given that the financial data fell short of market expectations, investors may adopt a cautious stance regarding the company's future performance, potentially leading to stock price volatility and affecting the company's financing capabilities.
See More
Cosmos Health Completes Liv18™ Development Ahead of Schedule
- Development Milestone: Cosmos Health has successfully completed the product development, packaging, and initial commercial setup for Liv18™ ahead of schedule, with production expected to commence in April 2026, accelerating its market rollout in the U.S.
- High-Standard Manufacturing: Liv18™ will be produced in GMP-certified, FDA-registered, and UL-audited facilities in the U.S., which not only ensures product quality and safety but also mitigates tariff risks and enhances supply chain efficiency.
- Optimistic Revenue Projections: Liv18™ is expected to generate over $5 million in annual revenue with approximately 75% gross margins, indicating its premium market positioning and direct-to-consumer business model will significantly enhance the company's overall profitability.
- Strategic Market Investment: Cosmos Health prioritizes the U.S. as a key growth market and is making targeted investments to drive scalable growth, with CEO Greg Siokas emphasizing that Liv18™ will serve as a meaningful incremental revenue driver, supporting a significant uplift in profitability.
See More
Cosmos Holdings Reports 83% Revenue Growth in FY 2025
- Revenue and Gross Profit Growth: Cosmos Holdings reported FY 2025 revenue of $65.27 million, an 83% increase from the previous year, with gross profit rising from $4.31 million in FY 2024 to $7.90 million, indicating positive impacts from improved product mix and contributions from higher-margin divisions.
- Gross Margin Expansion: The gross margin improved significantly from 7.92% in FY 2024 to 12.10%, representing a 418-basis point enhancement, reflecting the company's operational efficiencies.
- Increase in Operating Expenses: Total operating expenses rose to $24.60 million, compared to $19.86 million in FY 2024, primarily due to strategic investments in talent and new hires, as well as corporate growth initiatives supporting global expansion.
- Widening Net Loss: The net loss increased to $19.14 million from $16.18 million in FY 2024, with adjusted net loss at $5.98 million, primarily reflecting higher costs associated with business expansion and growth initiatives.
See More
Cosmos Health Reports No Impact from Middle East Tensions
- Operational Stability: Cosmos Health stated that the Iran conflict and broader Middle East tensions have had no material impact on its operations or supply chain, ensuring the company's stability and continued growth in uncertain environments.
- Profitability Outlook: The company reaffirmed its strong growth momentum, expecting approximately 75% gross margins from U.S. operations, which will lay a solid foundation for future profitability.
- NOOR Project Projections: The NOOR project is projected to generate over $12 million in revenue over the next 12 months, further driving the company's overall financial performance and market confidence.
- Enhanced Market Confidence: With ongoing growth and profitability expectations, Cosmos Health's market confidence is bolstered, potentially attracting more investor attention to its future development prospects.
See More
Cosmos Health Projects NOOR Collagen to Generate Over $12 Million Annually
- Revenue Projection: Cosmos Health anticipates that its NOOR Collagen supplement will generate over $12 million in annual revenue, indicating strong market demand and profitability potential, thereby reinforcing the company's position in the nutraceutical sector.
- Acquisition Strategy: The firm is in the process of acquiring a Greece-based pharmacy distribution network with approximately $11.5 million in annual revenue, which not only aids in expanding market share but also supports the company's goal of achieving $155.8 million in revenue by 2027.
- Stock Performance: Currently trading around $0.3, significantly below book value, management indicated that proceeds from potential capital-raising efforts may be used for strategic investments and share buybacks, enhancing shareholder value.
- Market Sentiment Shift: Investor sentiment on Stocktwits shifted from neutral to bullish, although opinions on stock price direction vary, with some users predicting a 90% to 95% increase from record lows, while others believe there is still room for further declines.
See More
Cosmos Health Projects 207% Revenue Growth by 2029
- Revenue Growth Outlook: Cosmos Health anticipates revenue will increase from $65.3 million in 2025 to $200.6 million by 2029, representing a 207% growth at a 32% CAGR, primarily driven by strong growth in pharmaceutical distribution and nutraceutical commercialization.
- Significant Gross Profit Increase: Gross profit is projected to rise 801% from $7.9 million in 2025 to $71.2 million by 2029, with gross margins expanding from 12.1% to 35.5%, reflecting a strategic shift towards higher-margin proprietary products.
- Net Income Turnaround: The company expects to achieve profitability in 2027, with net income projected to reach $31.0 million by 2029, an improvement of $50.1 million from a loss in 2025, indicating substantial gains in revenue and cost efficiencies.
- Positive Cash Flow Transition: Operating cash flow is expected to turn positive in 2027 at $11.9 million and increase to $24.0 million by 2029, demonstrating the company's shift towards a self-funding growth model.
See More
Cosmos Holdings Reports Q1 Financial Results
- Financial Performance: Cosmos Holdings reported an adjusted net loss of $996,502 for Q1, indicating challenges in profitability, although revenue reached $17.93 million, suggesting potential for sales growth.
- Revenue Analysis: The company reported revenue of $65.27 million, which, despite fluctuations compared to Q1 performance, still demonstrates a degree of competitiveness in the market that may attract investor interest.
- Earnings Per Share: Cosmos Holdings' non-GAAP EPS was -$0.12, highlighting the urgency for the company to control costs and improve profitability, which could influence future investment decisions.
- Market Reaction: Given that the financial data fell short of market expectations, investors may adopt a cautious stance regarding the company's future performance, potentially leading to stock price volatility and affecting the company's financing capabilities.
See More
Cosmos Health Completes Liv18™ Development Ahead of Schedule
- Development Milestone: Cosmos Health has successfully completed the product development, packaging, and initial commercial setup for Liv18™ ahead of schedule, with production expected to commence in April 2026, accelerating its market rollout in the U.S.
- High-Standard Manufacturing: Liv18™ will be produced in GMP-certified, FDA-registered, and UL-audited facilities in the U.S., which not only ensures product quality and safety but also mitigates tariff risks and enhances supply chain efficiency.
- Optimistic Revenue Projections: Liv18™ is expected to generate over $5 million in annual revenue with approximately 75% gross margins, indicating its premium market positioning and direct-to-consumer business model will significantly enhance the company's overall profitability.
- Strategic Market Investment: Cosmos Health prioritizes the U.S. as a key growth market and is making targeted investments to drive scalable growth, with CEO Greg Siokas emphasizing that Liv18™ will serve as a meaningful incremental revenue driver, supporting a significant uplift in profitability.
See More
Cosmos Holdings Reports 83% Revenue Growth in FY 2025
- Revenue and Gross Profit Growth: Cosmos Holdings reported FY 2025 revenue of $65.27 million, an 83% increase from the previous year, with gross profit rising from $4.31 million in FY 2024 to $7.90 million, indicating positive impacts from improved product mix and contributions from higher-margin divisions.
- Gross Margin Expansion: The gross margin improved significantly from 7.92% in FY 2024 to 12.10%, representing a 418-basis point enhancement, reflecting the company's operational efficiencies.
- Increase in Operating Expenses: Total operating expenses rose to $24.60 million, compared to $19.86 million in FY 2024, primarily due to strategic investments in talent and new hires, as well as corporate growth initiatives supporting global expansion.
- Widening Net Loss: The net loss increased to $19.14 million from $16.18 million in FY 2024, with adjusted net loss at $5.98 million, primarily reflecting higher costs associated with business expansion and growth initiatives.
See More
Cosmos Health Reports No Impact from Middle East Tensions
- Operational Stability: Cosmos Health stated that the Iran conflict and broader Middle East tensions have had no material impact on its operations or supply chain, ensuring the company's stability and continued growth in uncertain environments.
- Profitability Outlook: The company reaffirmed its strong growth momentum, expecting approximately 75% gross margins from U.S. operations, which will lay a solid foundation for future profitability.
- NOOR Project Projections: The NOOR project is projected to generate over $12 million in revenue over the next 12 months, further driving the company's overall financial performance and market confidence.
- Enhanced Market Confidence: With ongoing growth and profitability expectations, Cosmos Health's market confidence is bolstered, potentially attracting more investor attention to its future development prospects.
See More
Cosmos Health Projects NOOR Collagen to Generate Over $12 Million Annually
- Revenue Projection: Cosmos Health anticipates that its NOOR Collagen supplement will generate over $12 million in annual revenue, indicating strong market demand and profitability potential, thereby reinforcing the company's position in the nutraceutical sector.
- Acquisition Strategy: The firm is in the process of acquiring a Greece-based pharmacy distribution network with approximately $11.5 million in annual revenue, which not only aids in expanding market share but also supports the company's goal of achieving $155.8 million in revenue by 2027.
- Stock Performance: Currently trading around $0.3, significantly below book value, management indicated that proceeds from potential capital-raising efforts may be used for strategic investments and share buybacks, enhancing shareholder value.
- Market Sentiment Shift: Investor sentiment on Stocktwits shifted from neutral to bullish, although opinions on stock price direction vary, with some users predicting a 90% to 95% increase from record lows, while others believe there is still room for further declines.
See More
